Daily zuranolone—a GABA receptor–binding steroid—was more effective than placebo at reducing symptoms of postpartum depression in women, according to a report published Wednesday in JAMA Psychiatry. Zuranolone, developed by Sage Therapeutics, is similar to brexanolone in its mechanism of action but can be taken orally. Brexanolone is the intravenous medication that in 2019 became the first to receive FDA approval for the treatment of postpartum depression.
